A total of 43 patients who recovered from the SARS-CoV-2 infection with mild pneumonia were included along with 45 healthy ...

The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.

Urcosmid is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, typically found on immune ...

Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported ...

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

RPESC-RPE-4W is a proprietary retinal pigment epithelium cell therapy for patients with dry age-related macular degeneration.

Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal ...

NCX 470 0.1% achieved an intraocular pressure of less than or equal to 18 mmHg compared to latanoprost 0.005% in the trial.

Phase 3 trials demonstrated ENCELTO significantly slowed macular photoreceptor loss in MacTel patients over 24 months.

In addition to comparable BCVA levels, the researchers concluded that the PDS implant “provides effective, durable, and ...

The findings were from 6 patients in the first low-dose cohort of the ongoing first-in-human trial (NCT04627428).

Physicians’ Education Resource (PER) has launched Retina Resource, a comprehensive source of education and information on the ...